Posted On: 11/10/2015 10:59:58 AM
Post# of 72440
BIG NEWS FROM CTIX EMAIL:
"We are pleased to report that we have submitted our first paper on Kevetrin and p53 for peer-review and publication at a relevant scientific journal. Now that significant clinical data has been collected on Kevetrin, it's time for us to begin publishing in peer-reviewed journals to complement the peer-reviewed data presented at oncology conferences. We believe that publications in scientific/medical journals will attract more attention towards Cellceutix and benefit our shareholders."
"We are pleased to report that we have submitted our first paper on Kevetrin and p53 for peer-review and publication at a relevant scientific journal. Now that significant clinical data has been collected on Kevetrin, it's time for us to begin publishing in peer-reviewed journals to complement the peer-reviewed data presented at oncology conferences. We believe that publications in scientific/medical journals will attract more attention towards Cellceutix and benefit our shareholders."
(0)
(0)Scroll down for more posts ▼
